Landmarks in hormonal therapy for prostate cancer

BJU International

Volumn 110, Issue SUPPL. 1, 2012, Pages 23-29

  Hammerer, Peter ^a   Madersbacher, Stephan ^b  

^a Academic Hospital Braunschweig   (Germany)

^b DANUBE HOSPITAL   (Austria)

Author keywords

androgen deprivation therapy; EAU Guidelines; LHRH agonists; LHRH antagonists; prostate cancer

Indexed keywords

ABARELIX; ABIRATERONE ACETATE; ALENDRONIC ACID; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CETRORELIX; CYPROTERONE ACETATE; DEGARELIX; DENOSUMAB; DIETHYLSTILBESTROL; ENZALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; NILUTAMIDE; ORTERONEL; PAMIDRONIC ACID; PLACEBO; PREDNISONE; TRIPTORELIN; ZOLEDRONIC ACID;

ADVANCED CANCER; ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; HUMAN; METASTASIS; NONHUMAN; ORCHIECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 84867551392     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11431.x     Document Type: Article

References (69)

1. Horwitz EM, Bae K, Hanks GE, et al,. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504
2. Heidenreich A, Bolla M, Joniau S, et al,. EAU Guidelines on Prostate Cancer 2011. Available at: http://www.uroweb.org/gls/pdf/08-Prostate- Cancer%20September%2022nd%202011.pdf. Accessed July 2012
3. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI,. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 1021-4
4. Morote J, Orsola A, Planas T, et al,. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-5 (Pubitemid 47368393)
5. Melton LJ 3rd, Alothman KI, Achenbach SJ, O'Fallon WM, Zincke H,. Decline in bilateral orchiectomy for prostate cancer in Olmsted county, Minnesota, 1956-2000. Mayo Clinic Proc 2001; 76: 1199-203 (Pubitemid 33117013)
6. Machtens S, Schultheiss D, Kuczyk M, Truss MC, Jonas U,. The history of endocrine therapy of benign and malignant diseases of the prostate. World J Urol 2000; 18: 222-6
7. Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-7
8. Byar DP, Corle DK,. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr 1988; 7: 165-70
9. The Leuprolide Study Group. Leuprolide versus diethylstilbesterol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-6
10. Schally AV,. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20: 1247-62 (Pubitemid 29512447)
11. Limonta P, Montagnani MM, Moretti RM,. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001; 10: 709-20 (Pubitemid 32288188)
12. Agarwal DK, Costello AJ, Peters J, Sikaris K, Crowe H,. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy. BJU Int 2000; 85: 690-5 (Pubitemid 30192836)
13. Labrie F, Dupont A, Belanger A, Emond J, Monfette G,. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 1984; 81: 3861-3 (Pubitemid 14087818)
14. Bubley GJ,. Is the flare phenomenon clinically significant? Urology 2001; 58 (Suppl. 1): 5-9 (Pubitemid 32743396)
15. Seidenfield J, Samson DJ, Hasselblad V, et al,. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77 (Pubitemid 30171897)
16. Mottet N, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83
17. McLeod DG, Zinner N, Tomera K, et al,. A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2003; 61 (Suppl. 1): 3-7
18. Trachtenberg J, Gittleman M, Steidle C, et al,. A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 1670-4 (Pubitemid 34240698)
19. Tombal B, Miller K, Boccon-Gibod L, et al,. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57: 836-42
20. Decensi AU, Boccardo F, Guarneri D, et al,. Monotherapy with nilutamide, a pure non-steroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991; 146: 377-81
21. Desai A, Stadler WM, Vogelzang N,. Nilutamide: possible utility as a second-line hormonal agent. Urology 2001; 58: 1016-20 (Pubitemid 34017291)
22. Kassouf W, Tanguay S, Aprikian AG,. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003; 169: 1742-44 (Pubitemid 36443485)
23. Tyrrell CJ, Kaisary AV, Iversen P, et al,. A randomized comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56 (Pubitemid 28251992)
24. Iversen P, Tyrrell CJ, Kaisary AV, et al,. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 2000; 164: 1579-82
25. Boccardo F, Barichello M, Battaglia M, et al,. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002; 42: 481-90 (Pubitemid 35402048)
26. Heidenreich A,. Current approach to androgen deprivation therapy in patients with advanced prostate cancer. Eur Urol 2010; 9: 776-81
27. Walsh PC,. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975; 2: 125-140
28. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D,. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82 (Pubitemid 20134481)
29. Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R,. The final analysis of the EORTC Genito-Urinary Tract cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 273-83
30. Mottet N, Costa P, Navratil H,. Intermittent versus continuous hormone deprivation in metastatic prostate cancer: preliminary data from an ongoing European study. Prost Canc Prostatic Dis 1999; 2 (Suppl. 2): S2-S4 (Pubitemid 30058708)
31. Theyer G, Hamilton G,. Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology 1998; 52: 353-9 (Pubitemid 28399897)
32. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD,. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate specific antigen. Cancer 1993; 71: 2782-90 (Pubitemid 23120055)
33. Sato N, Gleave ME, Bruchovsky N, et al,. Intermittent androgen suppression delays time to non-androgen regulated prostate specific antigen gene expression in the human prostate LNCaP tumor model. J Steroid Biochem Molec Biol 1996; 58: 139-46 (Pubitemid 26284510)
34. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P,. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Canc Prostat Dis 1998; 1: 289-96 (Pubitemid 128545877)
35. Woolf JM, Tunn UW,. Intermittent androgen blockade in prostate cancer: rational and clinical experience. Eur Urol 2000; 38: 365-71
36. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr,. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-50 (Pubitemid 17191621)
37. Crook JM, Szumacher E, Malone S, Huan S, Segal R,. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 530-4 (Pubitemid 29136197)
38. Kurek R, Renneberg H, Lübben G, Kienle E, Tunn UW,. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999; 35 (Suppl. 1): 27-31 (Pubitemid 29078480)
39. Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM,. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Urol Int 2005; 75: 204-8 (Pubitemid 41433866)
40. Calais da Silva FE, Bono AV, Whelan P, et al,. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-77
41. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59
42. Lundgren R, Nordle O, Josefsson K,. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicentre study with 15 years of followup. The South Sweden Prostate Cancer Study Group. J Urol 1995; 153: 1580-6
43. Wirth MP, See WA, McLeod DG, et al,. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865-70 (Pubitemid 39363075)
44. Schröder FH, Kurth KH, FossÃ¥ SD, et al,. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of the European Organization for the Research and Treatment of Cancer 30846-a phase III study. J Urol 2004; 172: 923-7 (Pubitemid 39096424)
45. Studer UE, Whelan P, Albrecht W, et al,. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. Clin Oncol 2006; 24: 1868-76 (Pubitemid 46638985)
46. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79: 235-46
47. Schröder FH, Kurth KH, Fossa SD, et al,. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009; 55: 14-22
48. Messing EM, Manola J, Yao J, et al,. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9 (Pubitemid 43779173)
49. Bolla M,. Current status of combined radiation therapy and androgen suppression in locally advanced prostate cancer: what is the way forward? Eur Urol 2010; 9 (Suppl.): 788-93
50. Pilepich MV, Winter K, Lawton CA, et al,. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma. Long- term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90 (Pubitemid 40470408)
51. Potosky AL, Legler J, Albertsen PC, et al,. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2000; 92: 1582-92
52. Isbarn H, Boccon-Gibod L, Carroll PR, et al,. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009; 55: 62-75
53. Ross RW, Small EJ,. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167: 1952-6 (Pubitemid 34309635)
54. Daniell HW,. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44 (Pubitemid 27026812)
55. Smith MR, Eastham J, Gleason DM, et al,. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-12 (Pubitemid 36576705)
56. Michaelson MD, Kaufman DS, Lee H, et al,. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-42 (Pubitemid 46596753)
57. Smith MR, Egerdie B, Hernández Toriz N, et al,. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55
58. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-8
59. Nguyen PL, Je Y, Schutz FA, et al,. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306: 2359-66
60. Auchus RJ,. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001; 30: 101-9 (vii)
61. Yap TA, Carden CP, Attard G, de Bono JS,. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008; 8: 449-57
62. Attard G, Reid AH, Yap TA, et al,. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71
63. Ryan CJ, Smith MR, Fong L, et al,. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-8
64. De Bono J, Logothetis CJ, Fizazi K, et al,. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized, double-blind, placebo controlled phase III study. 35th ESMO Congress 2010; Abstract LBA5
65. Kaku T, Hitaka T, Ojida A, et al,. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19: 6383-99
66. Dreicer R, Agus DB, MacVicar GR, et al,. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. Abstract presented at: 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco,CA, abstract 103
67. Hussain M, Corn P, Michaelson D, et al,. Activity and safety of the investigational agent orteronel in men with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen: results of a Phase 2 study. Eur Urol 2012; 11 (Suppl.): abstract 124
68. Tran C, Ouk S, Clegg NJ, et al,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90
69. Scher HI, Beer TM, Higano CS, et al,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46